查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1864291

月經症候群治療市場按治療方法、最終用戶和產品形式分類 - 全球預測 2025-2032 年

Premenstrual Syndrome Treatment Market by Treatment Type, End User, Product Form - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，月經症候群治療市場將成長至 25.5 億美元，複合年成長率為 4.47%。

關鍵市場統計數據
基準年 2024 17.9億美元
預計年份：2025年 18.7億美元
預測年份 2032 25.5億美元
複合年成長率 (%) 4.47%

全面概述影響經月經症候群治療策略的不斷演變的臨床複雜性、患者期望和護理路徑。

經月經症候群的症狀表現複雜多樣，涵蓋身體不適、情緒障礙和功能障礙等，需要採取多管齊下的治療方法。隨著臨床知識的不斷發展，人們逐漸揭示了荷爾蒙週期、神經傳導物質調節和心理社會因素之間的病理學生理聯繫，患者的期望也隨之轉變，他們希望獲得個別化治療方法，並盡可能減少對日常生活的干擾。因此，目前的治療方案更加多元化，結合了行為療法、營養補充劑和成熟的藥物療法，旨在解決整體症狀，而非僅僅針對單一症狀。

此外，醫療系統和臨床醫生正在整合遠距監測、分級診療通訊協定和明確的診斷標準，以縮短干預時間並滿足不斷變化的患者偏好。這些趨勢推動了對兼顧療效、耐受性和實際應用性的實證治療方案的需求。因此，從產品開發商到服務提供者，相關人員都在重新調整其臨床價值提案，強調日常功能的可衡量改善、有助於提高遵守用藥的治療形式以及補充（而非取代）標準治療的干涉措施。總而言之，這些發展正在為更完善的服務模式和商業性模式奠定基礎，這些模式和模式優先考慮以患者為中心的治療結果和可擴展的交付機制。

快速而變革性的轉變推動了數位化、個人化治療方法和綜合護理模式的發展，從而重塑了月經的治療。

月經症候群 (PMS) 的治療格局正在經歷變革，這主要得益於技術創新、對個人化醫療的重新關注以及臨床和消費者健康模式的融合。數位療法和遠端醫療平台能夠提供遠距認知行為療法和結構化的生活方式指導，從而擴大非藥物療法的覆蓋範圍，並有助於提高長期治療的依從性。同時，營養保健品科學和製劑技術的進步正在提高膳食補充劑的生物利用度和標準化程度，使其成為綜合護理計劃中可靠的輔助性治療。

同時，對神經內分泌調控的更深入理解正引領著藥物創新，使臨床醫生能夠更便捷地將現有藥物類別與標靶行為介入相結合，從而最佳化獲益風險比。醫療系統也正在嘗試整合式護理路徑，將症狀追蹤、療效評估和升級通訊協定納入其中，以便更好地根據患者需求調整介入強度。這些轉變為研發人員和醫療服務提供者帶來了新的策略要務。投資數位化、產生真實世界證據以及建立協作式照護框架，對於在不同的支付方和醫療服務環境中實現治療差異化、展現實際價值至關重要。

評估美國關稅到 2025 年對月經症候群 (PMS) 藥物供應鏈韌性、籌資策略和獲取動態的累積影響

美國關稅政策在2025年之前的變化正在對月經症候群（PMS）治療產品的供應鏈和成本結構產生顯著影響，尤其是那些依賴國際採購的活性藥物成分、特殊輔料和進口膳食補充劑成分的產品。為此，製造商和經銷商正努力透過重新評估籌資策略、優先考慮供應多元化以及加快庫存最佳化來減輕額外進口關稅的影響。這些營運調整通常包括在可行的情況下暫時將採購重新分配給國內供應商，並重新談判供應合約以吸收或轉嫁額外的到岸成本。

同時，臨床服務模式和終端使用者也在做出調整，以維持治療的可近性和可負擔性。醫院和專科診所正在加強採購通訊協定，並強調治療等效性評估，以確保在某些產品線價格可能波動的情況下，也能確保治療的連續性。居家照護模式和遠距配藥正受到越來越多利害關係人的青睞，他們希望在維持病患用藥依從性的同時，最大限度地降低與醫療機構供應鏈相關的不斷上漲的成本。最終，關稅環境正在強化靈活生產、透明的成本模式以及監管前瞻性對於開發和提供月經症候群 (PMS) 治療藥物的公司的重要性，促使這些公司將策略重點放在增強自身韌性而非短期價格調整上。

關鍵的細分洞察表明，治療類型、最終用戶趨勢和產品形式偏好相互融合，共同決定了月經症候群 (PMS)治療方法的採納和實施。

對治療細分市場的詳細分析突顯了治療方法選擇、護理環境和產品形式如何相互作用，從而影響臨床應用和患者體驗。在考慮治療類型時，認知行為療法和結構化生活方式管理等非藥物療法在早期療育路徑中發揮日益重要的作用。同時，膳食補充劑佔據獨特的市場地位，其配方至關重要。胺基酸衍生物、草藥萃取物以及維生素和礦物質補充劑各自都有其自身的證據要求和監管考量，這些都會影響臨床醫生的接受度和患者的信心。此外，按藥物類別分類的藥物治療對於中重度症狀仍然至關重要，其中複方口服避孕藥、GABA類似物和選擇性血清素再回收抑制劑（SSRIs）構成了臨床實踐中治療方法的基石。

最終用戶環境進一步影響藥物的選擇和給藥方式：居家照護環境傾向於採用能夠實現自我給藥和遠端支持的干涉措施；醫院優先考慮急性症狀控制和多學科協作；而專科診所通常是製定個體化治療方案和進行高級治療方案排序的中心。劑型影響著患者的依從性和製劑策略：膠囊、口服溶液和片劑在劑量靈活性、偏好和穩定性方面各有優勢，這些優勢決定了產品開發的優先順序。整合這些細分維度表明，成功的產品必須在特定治療領域內滿足證據閾值，同時還要根據不同環境（居家醫療、醫院和專科診所）的實際情況調整產品劑型和給藥模式。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和差異化策略路徑正在影響治療優先事項和進入模式。

區域趨勢揭示了美洲、歐洲、中東和非洲以及亞太地區在臨床實踐規範、法規環境和分銷基礎設施等方面存在的差異，從而形成了不同的戰略重點。在美洲，成熟的藥物治療和非藥物治療相結合的醫療模式是其特點，同時，公共和私人支付方的考慮也會影響藥物處方集的納入和輔助性治療的報銷。這種格局促使人們產生證據，以證明能夠帶來功能性獲益並減少後續藥物使用的成本效益高的治療路徑。

在歐洲、中東和非洲，分散的法規結構和多元化的支付方環境構成了複雜的准入壁壘，但也促進了區域性創新，尤其是在遠端醫療和社區服務能夠擴大覆蓋範圍的地區。本地化生產能力和監管協調工作對於決定哪些劑型和補充劑能夠獲得市場認可至關重要。與此同時，亞太地區正經歷著數位基礎設施的快速發展以及對膳食補充劑和具有文化底蘊的草藥療法的強勁需求。加之遠距遠端醫療模式的加速普及和消費者健康技術的蓬勃發展，企業必須根據各地區的關鍵臨床和支付方趨勢調整其監管策略、證據包和分銷模式，才能實現產品的持續推廣。

月經症候群 (PMS) 治療生態系統中的競爭與策略公司洞察：識別關鍵能力、合作機會、監管差異和差距

在經前症候群（月經）治療領域，競爭地位更取決於產品系列的深度、可靠的實證醫學證據以及跨通路夥伴關係，而非單一產品的突破性進展。擁有成熟荷爾蒙和神經調節藥物產品組合的製藥公司，透過將臨床試驗結果與真實世界的依從性研究和臨床醫生合作相結合，保持著競爭優勢。同時，能夠證明其原料來源穩定、批次間品質可靠且配方達到臨床級別的專業營養保健品生產商和合約開發商，對臨床醫生和大型經銷商的吸引力也日益增強。從遠端醫療平台到數位化症狀追蹤器，技術賦能的醫療服務提供者憑藉其整合能力脫穎而出，將行為介入與臨床監測和數據收集相結合。

隨著製造商尋求將藥物治療方案與數位治療方法和實證補充劑相結合，以建立全面的治療路徑，這些組成部分之間的策略聯盟也變得越來越普遍。監管核准、品質認證和透明的供應鏈實務仍然是關鍵的差異化因素，而那些投資於療效比較研究和與支付方合作的公司則更有能力影響採購決策。最終，能夠提供兼具臨床可靠性和可擴展交付能力，以適應不同終端用戶環境的產品和服務的企業，以獲得競爭優勢。

為產業領導者提供切實可行的策略建議，以推動PMS治療和服務交付的普及、最佳化獲取途徑並提供綜合價值。

產業領導者應優先採取一系列協作行動，以加速產品應用、確保產品可及性，並在臨床和商業管道中創造永續價值。首先，投資於將介入措施與功能性結果聯繫起來的高品質證據，將有助於提升與臨床醫生和支付方的合作關係，並促進其融入治療路徑。其次，開發可與藥物和補充劑配送相結合的互通性數位工具和遠端醫療項目，能夠提高患者的用藥依從性，並支持長期療效評估。此外，還應輔以穩健的生產和供應鏈策略，以減少對單一供應商的依賴，並增強應對力關稅和貿易政策變化的能力。

此外，應積極尋求跨領域夥伴關係，將製藥專業知識、營養保健品製劑技術和數位化互動相結合，以提供能夠反映患者實際需求的多方面治療方案。應根據不同地區最佳化市場進入策略，使監管和報銷策略與當地醫療保健系統的發展趨勢保持一致。最後，落實以患者為中心的產品設計，例如採用適應性強的劑型、易於吞嚥的口服液以及方便使用的膠囊和片劑，將有助於提高產品在包括居家醫療、醫院和專科診所在內的各種醫療環境中的接受度，從而提升實際應用效果和臨床療效。

透明的多方法調查方法為 PMS 治療分析提供了基礎，包括資料收集的檢驗、專家檢驗和清晰的分析框架。

本分析採用多方法研究途徑，優先考慮對一級資訊來源和二級資訊來源進行三角檢驗。一級資訊來源包括對臨床醫生、藥屋主任、採購人員和技術提供者的結構化訪談，旨在了解他們對治療效果、交付挑戰和推廣應用促進因素的現場觀點。二級資訊來源包括同行評審的臨床文獻、監管指導文件、產品標籤和公共臨床試驗註冊庫，用於支持作用機制、安全性特徵和治療定位。資料綜合採用主題分析法辨識重複出現的模式，並採用比較評估法揭示區域差異。

透過迭代檢驗循環來保持分析的嚴謹性，在循環中，與領域專家討論初步發現，以完善假設並識別潛在偏差。透過情境分析評估供應鏈和政策影響，該分析考慮了與關稅相關的物流、採購替代方案和採購應對措施，並專注於營運可行性。調查方法強調資訊來源歸屬和背景考慮的透明度，使相關人員能夠確定研究結果對其策略挑戰和區域環境的適用性。

綜合分析整合了臨床趨勢、監管影響和商業性訊號，為經前症候群 (PMS) 護理領域的相關人員確定切實可行的下一步措施。

總體而言，經前症候群（月經）治療格局的演變呈現出向以患者為中心的綜合治療模式轉變的趨勢，這種模式結合了行為療法、營養補充劑和藥物治療。臨床和治療方式的創新正在拓展有效的干​​預措施範圍，同時，實證醫學、品質和互通性的標準也在不斷提高。政策和貿易因素凸顯了建立具有韌性的供應鏈和適應性籌資策略的必要性，而區域間法規和治療模式的差異則表明，個人化規劃比一刀切的方法更為重要。

展望未來，相關人員投資於嚴謹的療效評估、構建涵蓋膠囊、口服液和片劑等多種劑型的靈活產品系列，並利用數位化平台支持患者依從性的利益相關者，將更有能力滿足醫療專業人員和患者的期望。製藥、營養保健品和數位醫療領域的合作對於將臨床潛力轉化為切實可行、可擴展的治療方案至關重要。最終，最成功的策略將平衡科學可靠性和營運靈活性，從而為經月經患者帶來顯著的日常功能改善。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 推廣個人化基因譜分析以進行月經的標靶治療
  • 將人工智慧驅動的症狀預測工具整合到月經症候群管理應用程式中
  • 利用遠端醫療擴大諮商系統，改善經月經症候群治療的可近性
  • CBD和類大麻素製劑在緩解月經症候群（PMS）相關症狀的應用日益廣泛
  • 將正念減壓療法引入經前症候群治療通訊協定
  • 微生物組創新－標靶治療緩解經月經症狀嚴重程度的差異
  • 增加對植物來源原臨床試驗的投資，以期緩解經前症候群的生理和情緒症狀。
  • 制定職場政策，為應對月經症狀提供彈性的休假安排
  • 擴大保險覆蓋範圍，涵蓋全面的月經健康護理，包括月經症候群（PMS）管理療法。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依治療方式分類的月經症候群治療市場

  • 非藥物治療
    • 認知行為療法
    • 生活方式管理
    • 營養補充品
      • 胺基酸衍生物
      • 草藥萃取物
      • 維生素和礦物質
  • 藥物治療
    • 按藥物類別
      • 口服避孕藥
      • GABA類似物
      • 選擇性血清素再回收抑制劑

第9章 依最終使用者分類的經月經症候群治療市場

  • 居家醫療環境
  • 醫院
  • 專科診所

第10章 依產品類型月經症候群治療市場

  • 膠囊
  • 口服液
  • 藥片

第11章 各地區經月經症候群治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 按組別分類的月經症候群治療市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 各國經月經症候群治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Bayer AG
    • Pfizer Inc.
    • Johnson & Johnson Services, Inc.
    • Eli Lilly and Company
    • GlaxoSmithKline plc
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Novartis AG
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-4F1ADAF481D9

The Premenstrual Syndrome Treatment Market is projected to grow by USD 2.55 billion at a CAGR of 4.47% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.79 billion
Estimated Year [2025] USD 1.87 billion
Forecast Year [2032] USD 2.55 billion
CAGR (%) 4.47%

Comprehensive contextual overview of the evolving clinical complexities patient expectations and care pathways shaping premenstrual syndrome treatment strategies

Premenstrual syndrome continues to present a complex constellation of symptoms that span physical discomfort, mood disturbance, and functional impairment, demanding multidisciplinary attention. Recent advances in clinical understanding have clarified pathophysiologic pathways that link hormonal cycling, neurotransmitter modulation, and psychosocial triggers, while patient expectations increasingly favor individualized and minimally disruptive interventions. Consequently, care pathways now reflect a broader palette of options that combine behavioral strategies, nutraceuticals, and established pharmacotherapies to address symptom clusters rather than single complaints.

Moreover, health systems and clinicians are responding to shifting patient preferences by integrating remote monitoring, stepped-care protocols, and clearer diagnostic criteria to reduce time to intervention. These trends are amplifying demand for evidence-backed therapeutic alternatives that balance efficacy, tolerability, and real-world usability. As a result, stakeholders from product developers to service providers are reframing clinical value propositions to emphasize measurable improvements in daily functioning, adherence-friendly formats, and interventions that complement rather than replace standard medical care. Taken together, these developments set the stage for more nuanced service models and commercial approaches that prioritize patient-centric outcomes and scalable delivery mechanisms.

Rapid transformative shifts driving digital enablement personalized therapeutic approaches and integrated care models reshaping premenstrual syndrome treatment

The landscape for premenstrual syndrome treatment is undergoing transformative shifts driven by technological innovation, a renewed focus on personalized care, and the convergence of clinical and consumer health paradigms. Digital therapeutics and telehealth platforms are enabling remote cognitive behavioral therapy and structured lifestyle coaching, which in turn are expanding access to non-pharmacological interventions and supporting long-term adherence. Simultaneously, advances in nutraceutical science and formulation techniques are improving the bioavailability and standardization of supplements, thereby making them more credible adjuncts within comprehensive care plans.

In parallel, pharmacological innovation is being informed by deeper insights into neuroendocrine modulation, with clinicians more readily combining established drug classes with targeted behavioral interventions to optimize benefit-risk profiles. Health systems are also experimenting with integrated care pathways that embed symptom tracking, outcome measurement, and stepped escalation protocols to better match intervention intensity to patient needs. These shifts are creating new strategic imperatives for developers and providers: investments in digital enablement, real-world evidence generation, and collaborative care frameworks are becoming essential to differentiate therapeutic offerings and to demonstrate tangible value across diverse payers and delivery settings.

Assessment of the cumulative impact of United States tariffs through 2025 on supply chain resilience procurement strategies and access dynamics for PMS treatments

Tariff policy changes in the United States through 2025 have exerted a measurable influence on the supply chains and cost structures that underpin premenstrual syndrome treatment delivery, particularly for products that rely on internationally sourced active pharmaceutical ingredients, specialty excipients, and imported nutraceutical components. Manufacturers and distributors have responded by reassessing sourcing strategies, prioritizing supplier diversification, and accelerating inventory optimization to mitigate exposure to incremental import duties. These operational adjustments have, in many cases, led to temporary reallocation of sourcing to domestic suppliers where feasible and to renegotiation of supplier agreements to absorb or pass through incremental landed costs.

At the same time, clinical service models and end users have adapted to preserve access and affordability. Hospitals and specialty clinics have tightened procurement protocols and emphasized therapeutic equivalence assessments to maintain continuity of care despite potential price movement in specific product lines. Home care models and remote dispensing have gained traction as stakeholders seek to preserve adherence while minimizing cost inflation associated with facility-based supply chains. Ultimately, the tariff environment has reinforced the importance of flexible manufacturing, transparent cost modeling, and regulatory foresight for companies engaged in developing or delivering treatments for premenstrual syndrome, prompting a strategic focus on resilience rather than short-term repricing.

Key segmentation insights revealing how treatment type end-user dynamics and product form preferences converge to determine therapeutic adoption and delivery for PMS care

A granular view of treatment segmentation highlights how therapeutic choices, care settings, and product formats intersect to shape clinical adoption and patient experience. When considering treatment type, non-pharmacological approaches such as cognitive behavioral therapy and structured lifestyle management play an increasingly central role in early intervention pathways, while nutritional supplements occupy a distinct niche where formulation matters; supplements based on amino acid derivatives, herbal extracts, and vitamins and minerals each present unique evidence requirements and regulatory considerations that influence clinician acceptance and patient trust. Conversely, pharmacological treatments organized by drug class remain essential for moderate to severe symptom profiles, with combined oral contraceptives, GABA analogs, and selective serotonin reuptake inhibitors forming the backbone of therapeutic regimens used in clinical practice.

End-user contexts further modulate preference and delivery: home care settings favor interventions that enable self-administration and remote support, hospitals prioritize acute symptom control and multidisciplinary coordination, and specialty clinics often serve as centers for tailored regimens and advanced therapeutic sequencing. Product form influences adherence and formulation strategy; capsules, oral liquids, and tablets each present distinct advantages related to dosing flexibility, palatability, and stability, which in turn inform product development priorities. Integrating these segmentation dimensions reveals that successful offerings will address evidence thresholds for specific therapeutic classes while aligning product form and delivery models to the operational realities of home care, hospital, and specialty clinic settings.

Regional dynamics and differentiated strategic trajectories across the Americas Europe Middle East & Africa and Asia-Pacific that shape treatment priorities and access models

Regional dynamics reveal differentiated strategic priorities driven by clinical practice norms, regulatory environments, and distribution infrastructures across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, care models are characterized by a mature mix of pharmacological and non-pharmacological adoption augmented by private and public payer considerations that influence formulary placement and reimbursement of adjunctive therapies. This context incentivizes evidence generation that demonstrates functional benefits and cost-effective care pathways that reduce downstream utilization.

Across Europe, the Middle East and Africa, fragmented regulatory frameworks and diverse payer landscapes create complex entry barriers but also enable region-specific innovation, particularly where telehealth and community-based delivery can expand reach. Local manufacturing capabilities and regulatory harmonization efforts are pivotal in determining which product forms and supplements gain traction. Meanwhile, the Asia-Pacific region combines rapidly expanding digital infrastructure with strong demand for nutraceuticals and culturally embedded herbal approaches, and this is complemented by accelerated adoption of remote care models and consumer-facing health technologies. Taken together, these regional trajectories suggest that companies must tailor regulatory strategies, evidence packages, and distribution models to the predominant clinical and payer dynamics of each geography to achieve sustainable adoption.

Competitive and strategic company insights identifying capability strengths partnership opportunities regulatory differentiators and gaps within the PMS treatment ecosystem

Competitive positioning within the premenstrual syndrome treatment ecosystem is defined less by single product breakthroughs and more by portfolio depth, evidence robustness, and cross-channel partnerships. Pharmaceutical companies with established portfolios in hormonal and neuro-modulatory classes retain advantages when they pair clinical trial outcomes with real-world adherence programs and clinician engagement. At the same time, specialist nutraceutical manufacturers and contract developers that can demonstrate consistent sourcing, batch-to-batch quality, and clinical-grade formulation are increasingly attractive to both clinicians and large-scale distributors. Technology-enabled providers-ranging from teletherapy platforms to digital symptom trackers-are differentiating through integration capabilities that link behavioral interventions with clinical oversight and data capture.

Strategic collaborations between these constituents are becoming more common, as manufacturers seek to bundle pharmacological options with digital therapeutics or evidence-based supplementation to create comprehensive care pathways. Regulatory approvals, quality certifications, and transparent supply chain practices continue to be key differentiators, and companies that invest in comparative-effectiveness research and payer engagement are better positioned to influence procurement decisions. Ultimately, competitive advantage accrues to organizations that can align clinical credibility with scalable delivery and that can adapt product and service offerings to diverse end-user settings.

Actionable strategic recommendations for industry leaders to enhance adoption optimize access and deliver integrated value across PMS therapeutic and service offerings

Industry leaders should prioritize a set of coordinated actions that accelerate adoption, preserve access, and create durable value across clinical and commercial channels. First, investing in high-quality evidence that links interventions to functional outcomes will strengthen positioning with clinicians and payers and will facilitate integration into care pathways. Second, developing interoperable digital tools and telehealth-enabled programs that can be bundled with pharmacological or supplement offerings will improve adherence and support longitudinal outcome measurement. These capabilities should be complemented by robust manufacturing and supply chain strategies that reduce dependence on single-source imports and that enhance responsiveness to tariff or trade-policy shifts.

In addition, organizations ought to pursue cross-sector partnerships that combine pharmaceutical expertise, nutraceutical formulation, and digital engagement to offer multi-modal therapeutic packages that reflect real-world patient needs. Strategic market entry should be regionally tailored, with regulatory and reimbursement strategies aligned to local health system dynamics. Finally, operationalizing patient-centric product design-through adaptable dosing formats, palatable oral liquids, and user-friendly capsule or tablet options-will increase acceptance across home care, hospital, and specialty clinic settings, thereby improving real-world uptake and clinical impact.

Transparent multi-method research methodology outlining data collection triangulation expert validation and analytical frameworks underpinning the PMS treatment analysis

This analysis was developed using a multi-method research approach that prioritized triangulation and validation across primary and secondary sources. Primary inputs included structured interviews with clinicians, pharmacy leaders, procurement specialists, and technology providers to capture frontline perspectives on therapeutic effectiveness, delivery challenges, and adoption drivers. Secondary sources encompassed peer-reviewed clinical literature, regulatory guidance documents, product labeling, and publicly available clinical trial registries to corroborate mechanism-of-action, safety profiles, and therapeutic positioning. Data synthesis relied on thematic analysis to identify recurring patterns and on comparative assessment to surface region-specific distinctions.

Analytical rigor was maintained through iterative validation cycles, wherein preliminary findings were reviewed with domain experts to refine assumptions and to identify potential bias. Supply chain and policy impacts were assessed through scenario analysis that considered tariff-related logistics, sourcing alternatives, and procurement responses, with attention to operational feasibility. The methodology emphasizes transparency in source attribution and contextual caveats so that stakeholders can judge the applicability of findings to their strategic questions and regional contexts.

Concluding synthesis integrating clinical trends regulatory influences and commercial signals to define pragmatic next steps for stakeholders in PMS care

In synthesis, the evolving landscape for premenstrual syndrome treatment is defined by a move toward integrated, patient-centered care that blends behavioral, nutraceutical, and pharmacological approaches. Clinical and delivery innovations are expanding the range of viable interventions while also raising the bar for evidence, quality, and interoperability. Policy and trade factors have highlighted the need for resilient supply chains and adaptive procurement strategies, and regional differences in regulation and care models underscore the necessity of tailored plans rather than one-size-fits-all rollouts.

Looking ahead, stakeholders who invest in rigorous outcome measurement, who build flexible product portfolios spanning capsules, oral liquids, and tablets, and who leverage digital platforms to support adherence will be best positioned to meet clinician and patient expectations. Collaboration across pharmaceutical, nutraceutical, and digital health domains will be essential to convert clinical promise into practical, scalable care. Ultimately, the most successful strategies will be those that balance scientific credibility with operational agility and that deliver demonstrable improvements in daily functioning for individuals affected by premenstrual syndrome.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rise of personalized genetic profiling for targeted premenstrual syndrome therapies
  • 5.2. Integration of AI powered symptom prediction tools into premenstrual syndrome management apps
  • 5.3. Expansion of telehealth based consultations for accessible premenstrual syndrome treatments
  • 5.4. Growing adoption of CBD and cannabinoid formulations for alleviating PMS related symptoms
  • 5.5. Integration of mindfulness based stress reduction programs in PMS treatment protocols
  • 5.6. Innovations in microbiome targeted therapies for mitigating premenstrual symptom severity fluctuations
  • 5.7. Increased investment in clinical trials for plant based adaptogens addressing PMS physical and emotional symptoms
  • 5.8. Development of workplace policies offering flexible leave for managing premenstrual syndrome symptoms
  • 5.9. Emergence of insurance coverage expansions for comprehensive menstrual health including PMS management therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Premenstrual Syndrome Treatment Market, by Treatment Type

  • 8.1. Non Pharmacological Treatment
    • 8.1.1. Cognitive Behavioral Therapy
    • 8.1.2. Lifestyle Management
    • 8.1.3. Nutritional Supplements
      • 8.1.3.1. Amino Acid Derivatives
      • 8.1.3.2. Herbal Extracts
      • 8.1.3.3. Vitamins & Minerals
  • 8.2. Pharmacological Treatment
    • 8.2.1. Drug Class
      • 8.2.1.1. Combined Oral Contraceptives
      • 8.2.1.2. Gaba Analogs
      • 8.2.1.3. Selective Serotonin Reuptake Inhibitors

9. Premenstrual Syndrome Treatment Market, by End User

  • 9.1. Home Care Settings
  • 9.2. Hospitals
  • 9.3. Specialty Clinics

10. Premenstrual Syndrome Treatment Market, by Product Form

  • 10.1. Capsule
  • 10.2. Oral Liquid
  • 10.3. Tablet

11. Premenstrual Syndrome Treatment Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Premenstrual Syndrome Treatment Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Premenstrual Syndrome Treatment Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Bayer AG
    • 14.3.2. Pfizer Inc.
    • 14.3.3. Johnson & Johnson Services, Inc.
    • 14.3.4. Eli Lilly and Company
    • 14.3.5. GlaxoSmithKline plc
    • 14.3.6. Teva Pharmaceutical Industries Ltd.
    • 14.3.7. Viatris Inc.
    • 14.3.8. Novartis AG
    • 14.3.9. Sanofi S.A.
    • 14.3.10. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. PREMENSTRUAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. PREMENSTRUAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PREMENSTRUAL SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GABA ANALOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GABA ANALOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GABA ANALOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GABA ANALOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GABA ANALOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GABA ANALOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 264. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2032 (USD MILLION)
  • TABLE 275. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 280. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 281. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 282. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 283. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 284. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 285. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-20